Abstract：
OBJECTIVE: This study aimed to elucidate the diagnostic roles of PAX8 immunohistochemistry in various ovarian tumors.
METHODS: We searched through the PubMed database and selected the eligible studies to perform the meta-analysis. The PAX8 immunohistochemical expression rates of various ovarian tumors, including primary and metastatic carcinomas, were analyzed. In addition, the subgroup analysis based on tumor behaviors was performed.
RESULTS: The PAX8 expression rates were 0.056 (95% confidence interval [CI] 0.008-0.307), 0.400 (95% CI 0.228-0.600), 0.741 (95% CI 0.578-0.857), and 0.738 (95% CI 0.666-0.799) in normal ovary and benign, borderline, and malignant ovarian tumors, respectively. The PAX8 expression rates of serous and transitional cell carcinomas were 0.937 (95% CI 0.882-0.967) and 0.918 (95% CI 0.841-0.959). In addition, the PAX8 expression rate of mucinous carcinomas was 0.393 (95% CI 0.285-0.512). However, metastatic carcinomas showed a significantly lower PAX8 expression rate than primary ovarian cancers (P < 0.001 in the meta-regression test). In cytologic specimens, PAX8 expression rates of serous and endometrioid carcinomas were 0.905 (95% CI 0.832-0.948) and 0.714 (95% CI 0.327-0.928), respectively.
CONCLUSIONS: PAX8 expression rate was significantly higher in serous ovarian tumors than in mucinous ovarian tumors. In addition, PAX8 expression rates were significantly higher in primary ovarian cancers than in metastatic carcinomas.
METHODS: We searched through the PubMed database and selected the eligible studies to perform the meta-analysis. The PAX8 immunohistochemical expression rates of various ovarian tumors, including primary and metastatic carcinomas, were analyzed. In addition, the subgroup analysis based on tumor behaviors was performed.
RESULTS: The PAX8 expression rates were 0.056 (95% confidence interval [CI] 0.008-0.307), 0.400 (95% CI 0.228-0.600), 0.741 (95% CI 0.578-0.857), and 0.738 (95% CI 0.666-0.799) in normal ovary and benign, borderline, and malignant ovarian tumors, respectively. The PAX8 expression rates of serous and transitional cell carcinomas were 0.937 (95% CI 0.882-0.967) and 0.918 (95% CI 0.841-0.959). In addition, the PAX8 expression rate of mucinous carcinomas was 0.393 (95% CI 0.285-0.512). However, metastatic carcinomas showed a significantly lower PAX8 expression rate than primary ovarian cancers (P < 0.001 in the meta-regression test). In cytologic specimens, PAX8 expression rates of serous and endometrioid carcinomas were 0.905 (95% CI 0.832-0.948) and 0.714 (95% CI 0.327-0.928), respectively.
CONCLUSIONS: PAX8 expression rate was significantly higher in serous ovarian tumors than in mucinous ovarian tumors. In addition, PAX8 expression rates were significantly higher in primary ovarian cancers than in metastatic carcinomas.
摘要：
目的：本研究旨在阐明PAX8免疫组织化学在各种卵巢肿瘤中的诊断作用。
方法：我们搜索了PubMed数据库，并选择了符合条件的研究进行荟萃分析。PAX8在各种卵巢肿瘤中的免疫组化表达率,包括原发性和转移性癌，进行了分析。此外,进行了基于肿瘤行为的亚组分析.
结果：PAX8表达率为0.056（95％置信区间[CI]0.008-0.307），0.400（95%CI0.228-0.600），0.741（95%CI0.578-0.857），和0.738（95％CI0.666-0.799）在正常卵巢和良性，边界线，卵巢恶性肿瘤，分别。浆液性和移行细胞癌的PAX8表达率分别为0.937（95％CI0.882-0.967）和0.918（95％CI0.841-0.959）。此外,粘液性癌的PAX8表达率为0.393（95％CI0.285-0.512）。然而,转移性癌的PAX8表达率显著低于原发性卵巢癌(meta回归检验P<0.001).在细胞学标本中，浆液性癌和子宫内膜样癌的PAX8表达率分别为0.905(95%CI0.832-0.948)和0.714(95%CI0.327-0.928),分别。
结论：PAX8在浆液性卵巢肿瘤中的表达率明显高于粘液性卵巢肿瘤。此外,原发性卵巢癌中的PAX8表达率明显高于转移癌。
方法：我们搜索了PubMed数据库，并选择了符合条件的研究进行荟萃分析。PAX8在各种卵巢肿瘤中的免疫组化表达率,包括原发性和转移性癌，进行了分析。此外,进行了基于肿瘤行为的亚组分析.
结果：PAX8表达率为0.056（95％置信区间[CI]0.008-0.307），0.400（95%CI0.228-0.600），0.741（95%CI0.578-0.857），和0.738（95％CI0.666-0.799）在正常卵巢和良性，边界线，卵巢恶性肿瘤，分别。浆液性和移行细胞癌的PAX8表达率分别为0.937（95％CI0.882-0.967）和0.918（95％CI0.841-0.959）。此外,粘液性癌的PAX8表达率为0.393（95％CI0.285-0.512）。然而,转移性癌的PAX8表达率显著低于原发性卵巢癌(meta回归检验P<0.001).在细胞学标本中，浆液性癌和子宫内膜样癌的PAX8表达率分别为0.905(95%CI0.832-0.948)和0.714(95%CI0.327-0.928),分别。
结论：PAX8在浆液性卵巢肿瘤中的表达率明显高于粘液性卵巢肿瘤。此外,原发性卵巢癌中的PAX8表达率明显高于转移癌。
